Antiemetic Choice in Children Under 2 Years
Ondansetron is the first-line antiemetic for children younger than 2 years, with established dosing of 0.15 mg/kg or 5 mg/m² for chemotherapy-induced nausea/vomiting, and a single oral dose for gastroenteritis-related vomiting.
Context-Specific Recommendations
For Chemotherapy-Induced Nausea/Vomiting
5-HT3 receptor antagonists (ondansetron or granisetron) are the preferred agents for pediatric patients receiving chemotherapy, as they have been shown superior to metoclopramide, phenothiazines, and cannabinoids with significantly less toxicity 1.
Ondansetron dosing: 0.15 mg/kg or 5 mg/m² administered once daily 1.
Granisetron dosing: 0.01 mg/kg or 10 µg/kg once daily 1.
Addition of dexamethasone to a 5-HT3 receptor antagonist is recommended for moderate to high emetogenic chemotherapy, though the risk-benefit profile in very young children requires careful consideration 1.
For Gastroenteritis-Related Vomiting
Ondansetron is the only antiemetic with high-quality evidence demonstrating effectiveness in reducing vomiting, preventing hospitalization, and decreasing the need for intravenous rehydration 2, 3.
A single oral dose of ondansetron reduces gastroenteritis-related vomiting and facilitates oral rehydration therapy without significant adverse events 4, 3, 5.
Ondansetron increases cessation of vomiting (odds ratio = 0.28,95% CI 0.16-0.46) and reduces hospitalization risk (odds ratio = 2.93,95% CI 1.69-6.18) compared to placebo 2.
Important Safety Considerations
Agents to Avoid in Young Children
Metoclopramide and phenothiazines have moderate efficacy but significant side effects, including marked sedation and extrapyramidal reactions, making them less suitable for infants 1.
Dimenhydrinate was the only intervention found to be worse than placebo when considering side effects 2.
Promethazine requires central line administration for IV use and carries risks of sedation 1.
Ondansetron-Specific Cautions
Ondansetron may increase episodes of diarrhea in gastroenteritis patients, though this does not outweigh its benefits in preventing dehydration 3.
The drug has been extensively studied in children as young as 3 months with good tolerability 6.
Clinical Algorithm for Antiemetic Selection
Step 1: Identify the cause of vomiting
- Chemotherapy-induced → Proceed to Step 2A
- Gastroenteritis-related → Proceed to Step 2B
Step 2A: For chemotherapy-induced vomiting
- Use ondansetron 0.15 mg/kg or granisetron 0.01 mg/kg 1
- Add dexamethasone for moderate-to-high emetogenic chemotherapy if age-appropriate 1
Step 2B: For gastroenteritis-related vomiting
- Administer single oral dose of ondansetron 4, 2, 3
- Use when vomiting hinders oral rehydration therapy 4, 5
- Monitor for increased diarrhea 3
Evidence Quality and Gaps
The evidence supporting ondansetron in children is robust, with multiple systematic reviews and meta-analyses demonstrating efficacy and safety 2, 3. However, most chemotherapy studies are small, making optimal dosing difficult to establish definitively 1. The use of ondansetron in gastroenteritis is considered "off-label/on-evidence," meaning it lacks formal approval for this indication but has substantial supporting data 5.
Key limitation: Most studies were conducted in secondary care settings, with limited data from primary care 3. Despite this, the consistent evidence of benefit supports ondansetron as the antiemetic of choice across settings for children under 2 years.